Lv1
18 积分 2021-03-15 加入
Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy
12天前
已完结
Immunotherapy in Extensive Stage Small-Cell Lung Cancer in First-Line and Second-Line Setting: A Systematic Review and Meta-Analysis
13天前
已关闭
Circulating Tumor Cells Predict Response to the DLL3-targeting Bispecific Antibody Tarlatamab
13天前
已完结
Integrated Gene Expression and Methylation Analyses Identify DLL3 as a Biomarker for Prognosis of Malignant Glioma
14天前
已完结
Characteristics of Notch signaling pathway and its correlation with immune microenvironment in SCLC
14天前
已完结
Delta-like ligand 3 (DLL3): an attractive actionable target in tumors with neuroendocrine origin
14天前
已关闭
Combining antibody-drug conjugates with immunotherapy in solid tumors: current landscape and future perspectives
26天前
已完结
Tumor microenvironment-mediated immune profiles and efficacy of anti-PD-L1 antibody plus chemotherapy stratified by DLL3 expression in small-cell lung cancer
26天前
已完结
Updated data from IMbrave050: Adjuvant atezolizumab plus bevacizumab for high-risk hepatocellular carcinoma
27天前
已完结
MUC17, a novel membrane-tethered mucin
1个月前
已完结
皖公网安备34019202002308
